Mirogabalin combined conventional therapy
PreclinicalSmall molecule
Mirogabalin combined conventional therapy is one of 28 small molecule programs targeting Herpes Zoster. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
92 competitors in Herpes Zoster
#DrugCompanyPhaseTrials
1Fluzone
SanofiPhase 3
Herpes Zoster Vaccine 1437173a
GSKPhase 3
GSK 257049
GSKPhase 3
Rsvpref3 Vaccine
GSKPhase 3
Boostrix
GSKPhase 3
Prevenar13
GSKPhase 3
Valtrex
GGlaxo Dba Glaxosmithkline
Phase 2
Hz/su VACCINE
GSKPhase 3
Valaciclovir
GSKPhase 2
Influenza Vaccine
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Herpes Zoster1 trial
The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster
Recruiting·—·N/A·NCT07307170·750 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBeijing Tiantan Hospital